Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The anti-SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination.
Benschop RJ, Tuttle JL, Zhang L, Poorbaugh J, Kallewaard NL, Vaillancourt P, Crisp M, Trinh TNV, Freitas JJ, Beasley S, Daniels M, Haustrup N, Higgs RE, Nirula A, Cohen MS, Marovich M. Benschop RJ, et al. Among authors: haustrup n. Sci Transl Med. 2022 Jul 27;14(655):eabn3041. doi: 10.1126/scitranslmed.abn3041. Epub 2022 Jul 27. Sci Transl Med. 2022. PMID: 35679357 Free PMC article. Clinical Trial.
Speed of clinical improvement in the real-world setting from patient-reported Psoriasis Symptoms and Signs Diary: Secondary outcomes from the Psoriasis Study of Health Outcomes through 12 weeks.
Reich A, Pinter A, Maul JT, Vender RB, Torres T, Brnabic A, Haustrup N, Reed C, Schuster C, Riedl E. Reich A, et al. Among authors: haustrup n. J Eur Acad Dermatol Venereol. 2023 Sep;37(9):1825-1840. doi: 10.1111/jdv.19161. Epub 2023 May 20. J Eur Acad Dermatol Venereol. 2023. PMID: 37147855
Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week 12 results from the observational Psoriasis Study of Health Outcomes (PSoHO).
Piaserico S, Riedl E, Pavlovsky L, Vender RB, Mert C, Tangsirisap N, Haustrup N, Gallo G, Schuster C, Brunner PM. Piaserico S, et al. Among authors: haustrup n. Front Med (Lausanne). 2023 Jun 29;10:1185523. doi: 10.3389/fmed.2023.1185523. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37457564 Free PMC article.
Baseline Characteristics and mNAPSI Change from Baseline Scores Through Month 12 for Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Nail Psoriasis Treated with Biologics from PSoHO.
Riedl E, Pinter A, Zaheri S, Costanzo A, Brnabic A, Konicek B, McKenzie R, Lampropoulou A, Rayes ME, Haustrup N, Schuster C. Riedl E, et al. Among authors: haustrup n. Dermatol Ther (Heidelb). 2024 May;14(5):1327-1335. doi: 10.1007/s13555-024-01150-y. Epub 2024 Apr 22. Dermatol Ther (Heidelb). 2024. PMID: 38649673
Comparative Effectiveness and Durability of Biologics in Clinical Practice: Month 12 Outcomes from the International, Observational Psoriasis Study of Health Outcomes (PSoHO).
Pinter A, Costanzo A, Khattri S, Smith SD, Carrascosa JM, Tada Y, Riedl E, Reich A, Brnabic A, Haustrup N, Lampropoulou A, Lipkovich I, Kadziola Z, Paul C, Schuster C. Pinter A, et al. Among authors: haustrup n. Dermatol Ther (Heidelb). 2023 Dec 19. doi: 10.1007/s13555-023-01086-9. Online ahead of print. Dermatol Ther (Heidelb). 2023. PMID: 38113010